GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » Asset Impairment Charge

Alphamab Oncology (STU:3NK) Asset Impairment Charge : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Asset Impairment Charge?

Alphamab Oncology's Asset Impairment Charge for the six months ended in Dec. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Alphamab Oncology Asset Impairment Charge Historical Data

The historical data trend for Alphamab Oncology's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Asset Impairment Charge Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Impairment Charge
Get a 7-Day Free Trial - - - - -

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alphamab Oncology Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Alphamab Oncology Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » Asset Impairment Charge
Comparable Companies
HKSE:02142 HKSE:06955 HKSE:02157 HKSE:01672 HKSE:02105 HKSE:02171 HKSE:02256 HKSE:02480 HKSE:02315 HKSE:01477 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
09966:Hong Kong
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Website
https://www.alphamabonc.com
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines